CXM Stock Chart & Stats
€446.00
€0.00(0.00%)
At close: 4:00 PM EDT
€446.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€316.00 - €478.00
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€6.06B
Enterprise Value€6.44K
Total Cash (Recent Filing)€40.22M
Total Debt (Recent Filing)€329.09M
Price to Earnings (P/E)27.2
Beta0.46
Next Earnings
Nov 03, 2026EPS Estimate
5.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)19.92
Shares Outstanding13,069,961
10 Day Avg. Volume5
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-2.78
Price to Book (P/B)6.29
Price to Sales (P/S)2.43
P/FCF Ratio18.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€491.49Price Target Upside10.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)21.34
Revenue Forecast (FY)€2.36B
Bulls Say, Bears Say
Bulls Say
VITAS Growth And GuidanceVITAS is expanding patient volume and census while management raises growth expectations. Sustained admissions and ADC gains can improve operating leverage and reinforce the hospice segment’s contribution to consolidated earnings.
Strong Cash GenerationOperating cash flow exceeds reported net income and free cash flow remains substantial, indicating strong earnings quality. This internally generated liquidity supports acquisitions, share repurchases and ongoing investment without relying heavily on external financing.
Roto-Rooter Commercial ExpansionThe commercial-manager model is producing materially stronger growth than branches without managers, suggesting a scalable execution advantage. Franchise acquisitions and broader commercial penetration could diversify demand beyond residential service calls over time.
Bears Say
Margin And Cash Flow PressureAlthough absolute profitability and cash generation remain healthy, weaker incremental free cash flow, lower margins and higher leverage indicate reduced financial momentum. If sustained, these pressures could constrain flexibility and make growth more dependent on execution.
Roto-Rooter Operating HeadwindsRoto-Rooter is needing more paid marketing to generate demand while water restoration remains disrupted by centralization. Persistent acquisition costs and weaker restoration economics could limit segment margins and offset commercial growth.
VITAS Regulatory And Mix RiskGreater hospice oversight may increase compliance costs, slow expansion or affect reimbursement practices. Separately, shorter stays and unfavorable acuity mix can reduce per-patient economics, creating lasting risk to VITAS growth and margins.
CXM FAQ
What was Chemed Corporation’s price range in the past 12 months?
Chemed Corporation lowest stock price was €316.00 and its highest was €478.00 in the past 12 months.
What is Chemed Corporation’s market cap?
Chemed Corporation’s market cap is €6.06B.
When is Chemed Corporation’s upcoming earnings report date?
Chemed Corporation’s upcoming earnings report date is Nov 03, 2026 which is in 68 days.
How were Chemed Corporation’s earnings last quarter?
Chemed Corporation released its earnings results on Jul 28, 2026. The company reported €5.193 earnings per share for the quarter, beating the consensus estimate of €4.799 by €0.394.
Is Chemed Corporation overvalued?
According to Wall Street analysts Chemed Corporation’s price is currently Undervalued.
Does Chemed Corporation pay dividends?
Chemed Corporation does not currently pay dividends.
What is Chemed Corporation’s EPS estimate?
Chemed Corporation’s EPS estimate is 5.55.
How many shares outstanding does Chemed Corporation have?
Chemed Corporation has 13,069,961 shares outstanding.
What happened to Chemed Corporation’s price movement after its last earnings report?
Chemed Corporation reported an EPS of €5.193 in its last earnings report, beating expectations of €4.799. Following the earnings report the stock price went down -1.316%.
Which hedge fund is a major shareholder of Chemed Corporation?
Currently, no hedge funds are holding shares in DE:CXM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Chemed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€491.49 (10.20% Upside)
€491.49 (10.20% Upside)
Blogger Sentiment
Bullish
DE:CXM Sentiment 75%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €3.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.98%
12-Months-Change
Fundamentals
Return on Equity
0.46%
Trailing 12-Months
Asset Growth
-8.05%
Trailing 12-Months
Company Description
Chemed Corporation
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
CXM Company Deck
CXM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was decidedly positive: VITAS delivered strong top-line and profitability beats, materially improved Medicare cap positioning, and management raised full-year guidance across ADC, revenue and EBITDA margin while consolidated cash generation exceeded expectations. Roto-Rooter showed commercial momentum, margin recovery in gross profit, and strategic franchise buybacks, but faces persistent lead-generation/marketing cost pressure, water restoration transitional issues and modest margin drag. Regulatory oversight and mix/length-of-stay dynamics at VITAS are noted risks but were framed as managed and not materially impairing guidance.View all DE:CXM earnings summariesCXM Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€491.49
▲(10.20% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Addus Homecare
―
Option Care Health
―
DaVita
―
National Healthcare
―
The Ensign Group
―








